tbuckley/cabot-search huggingface dataset:
AB0597 COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES IN KNEE OSTEOARTHRITIS
Authors: M. Yasmine, L. Souebni, S. Miladi, A. Fazaa, S. Mariem, K. Ouenniche, S. Kassab, S. Chekili, K. Ben Abdelghani, A. Laatar
Journal: Annals of the Rheumatic Diseases (2021)

Background: Knee osteoarthritis (OA) is a leading cause of disability among older adults. Recently, evidence-based guidelines for the comprehensive management of osteoarthritis (OA) were developed by the American College of Rheumatology (ACR). Objectives: The aim of this study was to assess compliance of doctors with ACR 2019 clinical practice guidelines for the management of knee OA. Methods: We conducted a prospective study including rheumatologists and general practitioners. The doctors were invited to answer a structured questionnaire via Google Form. The outcomes of interest concerned the medical management of knee OA as well as alternative medicine. Results: The study included 100 doctors: 75 rheumatologists and 25 general practitioners. Almost half of them (49%) have been practicing medicine for more than 10 years. Forty four percent of doctors see between 10 to 20 patients with knee OA per month and 47% of them declared seeing more than 20 patients. Regarding the pharmacological treatment of knee OA flares, oral Non-steroidal Anti-inflammatory drug (NSAIDs) was the initial molecule of choice (91%) followed by grade I analgesics (86 %) and topical NSAIDs (68%). Tramadol and non-Tramadol opioids as well as intraarticular glucocorticoid injections were prescribed respectively in 41% and 46 % of cases. Glucosamine and chondroitin sulfate were prescribed in 49% and 54% of cases respectively and as a combination in 20% of cases. The reasons for non-prescribing these molecules were non-affordable prices (n=19), a lack of efficacy (n=6) and potential sides effects (n=1). Seventy three percent of doctors prescribe hyaluronic acid injections, with a frequency of three weekly injections in 38.7 % of cases and according to the response to the first injection in 61.3% of cases. The combination of both corticosteroids and hyaluronic acid injection was preferred in 38% of cases. The majority of doctors (84%) referred their patients to physical therapy as a first-line prescription (82.1%) or after medical treatment failure (17.9%). The use of alternative medicine was at follows: acupuncture (42.7%), prolotherapy (28.1%) and platelet-rich plasma injections (16.7%). Thirty eight doctors recommended against alternative medicine. Conclusion: Our study showed a poor compliance to guidelines regarding the use of intra-articular injections and alternative medicine. Even though, these guidelines provide direction for clinicians, doctors and patients should engage in shared decision-making that accounts for patients’ values, preferences, and susceptibilities. Disclosure of Interests: None declared.
6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study
Authors: Justin Penner, Omar Abdel-Mannan, Karlie Grant, Sue Maillard, Filip Kucera, Jane Hassell, Michael Eyre, Zoe Berger, Yael Hacohen, Karyn Moshal, Michelle Wyatt, Lesley Cavalli, Mary Mathias, Alasdair Bamford, Delane Shingadia, Nele Alders, Louis Grandjean, Edward Gaynor, Rossa Brugha, Jelena Stojanovic, Mae Johnson, Elizabeth Whittaker, Ronit Pressler, Charalampia Papadopoulou
Journal: The Lancet Child & Adolescent Health (2021)
A Randomized Clinical Trial on Anterior Approach vs Conventional Hepatectomy for Resection of Colorectal Liver Metastasis—To Terminate or Not to Terminate the Study—Reply
Authors: Nuh N. Rahbari, Emrullah Birgin, Jürgen Weitz
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
In recurrent <i>C difficile</i> infection, oral FMT capsules have a pooled cure rate of 82% (low-quality evidence)
Authors: Laura C. Horton, Joseph D. Feuerstein
Journal: Annals of Internal Medicine (2021)

Source Citation Du C, Luo Y, Walsh S, Grinspan A. Oral fecal microbiota transplant capsules are safe and effective for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55:300-8. 33471490
OP0323-PARE “CELEBRATING THE 50TH ANNIVERSARY OF OUR ORGANISATION IN TIMES OF PANDEMIC: HOW WE USED DIGITAL TOOLS TO OVERCOME CHALLENGES AND DIFFICULTIES AND CAME INTO CONTACT WITH MORE PARTICIPANTS AND VIEWERS THAN EVER ENVISAGED!”
Authors: C. Elling-Audersch
Journal: Annals of the Rheumatic Diseases (2021)

Background: The German League against Arthritis (DRL) with about 300.000 members wanted to celebrate its 50 th anniversary in 2020. The original idea to perform a large jubilee gala was crossed by the limitation of contact and the precaution for members our organisation in times of pandemic. Objectives: It was a big challenge to transfer the celebration into a digital form in the pandemic. Our goal was to reach as many people (with RMDs, their family, colleagues, politicians) as possible, not only members of our organisation. We wanted to generate even more awareness for people with RMDs, their needs and difficulties nationwide. Methods: We decided to focus on digital formats and produced video clips and podcasts that were presented online. Some of the topics of the videos: Voluntary work, Young people with RMDs, Participation, Doctors and Patients as Partners. Furthermore, in 17 podcasts our member organisations highlighted their activities for people with RMDs. Volunteers vividly described their inside view in the podcasts. In addition, we created a historical timeline for the website. Special highlight was a radio programme based on our videos, summarising our activities that was broadcast by 19 radio stations. Results: The video clips attracted more viewers than could have been reached with an event in Berlin. For example we generated 35.000 viewers on our YouTube channel by presenting the birthday speech by our president. Altogether we reached successfully approximately 1.5 million people national wide. I will present the numbers of people our activities reached and feedback we received. Conclusion: We are convinced going on the right track using digital media as one of our priorities not only in times of pandemic but as a valuable enrichment for all RMD patients on national and international level. These examples of best practise experiences shall encourage other patient organisations to take on the challenge in pandemic times. By using digital tools and formats patient organisations can succeed in reaching more RMD patients and in staying connected with their members. Disclosure of Interests: None declared.
Effect of Six-Month Postoperative Endothelial Cell Density on Graft Survival after Descemet Membrane Endothelial Keratoplasty
Authors: Indrė Vasiliauskaitė, Ruth Quilendrino, Lamis Baydoun, Korine van Dijk, Gerrit R.J. Melles, Silke Oellerich
Journal: Ophthalmology (2021)
POS0784 AUDIOLOGIC EVALUATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IMPACT OF HYDROXYCHLOROQUINE THERAPY
Authors: S. Tharwat, W. Elshawaf, M. K. Nassar
Journal: Annals of the Rheumatic Diseases (2021)

Background: Hydroxychloroquine (HCQ) is a commonly used agent in the treatment of rheumatic diseases including systemic lupus erythematosus (SLE). [1] Objectives: The aim of this study was to evaluate the hearing function in SLE patients and assess the impact of chronic HCQ. Methods: This study was carried out on 60 individuals (48 SLE and 12 healthy controls). The SLE patients were divided into HCQ group (n=36) and non-HCQ group (n=12) according to the chronic administration of HCQ. All participants were assessed by full audiological history and extended high frequency audiometry at frequencies 9, 10, 11, 2, 12.5, 14, 16,18 and 20 KHz. Results: When comparing the study SLE patients with healthy controls,there was a statistically significant difference regarding patient reported otological manifestations such as tinnitus (p=.021), vertigo (p=.002) and hearing impairment (p=.042) while there was no significant difference regarding deafness or ear buzzing in one or both ears. HCQ group showed more hearing impairment at frequency 9000 and 20000 Hz than non-HCQ group (p=.004, &lt;.001 respectively). Conclusion: Otological symptoms and sensorineural hearing loss are prevalent among SLE patients. Chronic administration of HCQ may have an ototoxic effect. References: [1]Fiehn, C., et al. “Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.” Zeitschrift für Rheumatologie (2020): 1-9. Figure 1. Otological manifestations in the study SLE patients (n=48) and the healthy controls (n=12) Disclosure of Interests: None declared
AB0267 HOW EFFECTIVE IS PAIN MANAGEMENT IN THE PATIENTS’ OPINION? DATA FROM THE COMPAS STUDY
Authors: E. Pogozheva, A. Karateev, V. Amirdzhanova
Journal: Annals of the Rheumatic Diseases (2021)

Objectives: to evaluate the effectiveness and satisfaction of pain management in patients with rheumatic diseases (RD) according to a survey in the COMPAS (Quality of Pain Management according to Patients with Arthritis and Back pain) study. Methods: the survey involved 1040 patients with RD (rheumatoid arthritis-40.6%, osteoarthritis -32.1%, spondyloarthritis-10.6%, connective tissue diseases-8.6% of patients). 76.8% were women, the mean age was 55.8±14.0 years. 35.7% of patients continued to work in their specialty, 31.6% had various degrees of disability. The effectiveness of pain therapy was evaluated by the patient in the last month preceding the survey on a 5-point scale, where 1 - no effect and 5-excellent effect. Patients ‘ satisfaction with treatment, possible reasons for the lack of effectiveness of pain therapy and the use of additional treatment tools were also evaluated. Results: as therapy for the underlying disease, 40% of patients received conventional disease modifying antirheumatic drugs, 33.1% - glucocorticoids, 7.2% - biological agents and 15.2% - symptomatic slow-acting drugs in osteoarthritis. At the same time, 68% of patients needed additional analgesic therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Slightly less than half of the surveyed patients (46.9%) noted a moderate effect of analgesic therapy, 22.7% - a low effect and 5% - no effect, 23.7% rated the effectiveness of therapy as good and only 1.7% - as excellent. At the same time, only 15.6% of patients were completely satisfied with the result of NSAIDs, 64% were partially satisfied with the treatment and 20.4% were completely dissatisfied. As the reason of insufficient effectiveness of NSAIDs, most often (34.3%) patients named fear of adverse events associated with taking drugs, 19.4% - weak drugs, 15.3% - insufficient attention of doctors to complaints, 6.6% - poor diagnosis of the causes of pain. Others found it difficult to answer or were completely satisfied with the treatment. 40% of patients used additional methods, most often chiropractic (12.3%), acupuncture (4.8%), physiotherapy (12.7%) and folk remedies (7.4%). Conclusion: A significant proportion of patients with RD don’t have adequate pain control. Only 25.4% of patients rate the result of treatment as good and excellent, and even fewer patients (15.6%) are completely satisfied with the results of therapy. Thus, a personalized approach to analgesic therapy is necessary, taking into account the expectations of patients regarding the results of treatment. Disclosure of Interests: None declared
Positive Somatostatin Receptor Expression Demonstrated on 68Ga-NODAGA-LM3 PET/CT in a Neuroendocrine Tumor Patient With Negative Immunohistochemical Staining
Authors: Wenjia Zhu, Rongrui Liu, Lin Zhao, Li Huo
Journal: Clinical Nuclear Medicine (2021)

Abstract We present a case with pulmonary atypical carcinoid and multiple hepatic metastases. Immunohistochemical staining of liver biopsy sample was negative for somatostatin receptor subtype 2, but 68 Ga-NODAGA-LM3 PET/CT scan revealed multiple positive lesions. The mismatch was actually caused by heterogeneous expression of somatostatin receptor in liver lesions.
Novel insights into surfactant protein C trafficking revealed through the study of a pathogenic mutant
Authors: Jennifer A. Dickens, Eimear N. Rutherford, Susana Abreu, Joseph E. Chambers, Matthew O. Ellis, Annemarie van Schadewijk, Pieter S. Hiemstra, Stefan J. Marciniak
Journal: European Respiratory Journal (2021)

Alveolar epithelial cell dysfunction plays an important role in the pathogenesis of idiopathic pulmonary fibrosis (IPF), but remains incompletely understood. Some monogenic forms of pulmonary fibrosis are associated with expression of mutant surfactant protein C (SFTPC). The commonest pathogenic mutant, I73T, mislocalises to the alveolar epithelial cell plasma membrane and displays a toxic gain of function. Because the mechanisms explaining the link between this mutant and IPF are incompletely understood, we sought to interrogate SFTPC trafficking in health and disease to understand the functional significance of SFTPC-I73T relocalisation.We performed mechanistic analysis of SFTPC trafficking in a cell model that reproduces the in vivo phenotype and validated findings in human primary alveolar organoids.We show that wild-type SFTPC takes an unexpected indirect trafficking route via the plasma membrane and undergoes the first of multiple cleavage events before reaching the multivesicular body (MVB) for further processing. SFTPC-I73T takes this same route, but its progress is retarded both at the cell surface and due to failure of trafficking into the MVB. Unable to undergo onward trafficking, it is recycled to the plasma membrane as a partially cleaved intermediate.These data show for the first time that all SFTPC transits the cell surface during normal trafficking, and the I73T mutation accumulates at the cell surface through both retarded trafficking and active recycling. This understanding of normal SFTPC trafficking and how the I73T mutant disturbs it provides novel insight into SFTPC biology in health and disease, and in the contribution of the SFTPC mutant to IPF development.
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies
Authors: Can Li, Jiliang Xia, Reinaldo Franqui-Machin, Fangping Chen, Yanjuan He, Timothy Cody Ashby, Feixiang Teng, Hongwei Xu, Dingxiao Liu, Dongzheng Gai, Sarah K. Johnson, Frits van Rhee, Siegfried Janz, John D. Shaughnessy, Guido Tricot, Ivana Frech, Fenghuang Zhan
Journal: Journal of Clinical Investigation (2021)

Multiple myeloma (MM), a terminally differentiated B cell malignancy, remains difficult to cure. Understanding the molecular mechanisms underlying the progression of MM may identify therapeutic targets and lead to a fundamental shift in treatment of the disease. Deubiquitination, like ubiquitination, is a highly regulated process, implicated in almost every cellular process. Multiple deubiquitinating enzymes (DUBs) have been identified, but their regulation is poorly defined. Here, we determined that TRIP13 increases cellular deubiquitination. Overexpression of TRIP13 in mice and cultured cells resulted in excess cellular deubiquitination by enhancing the association of the DUB USP7 with its substrates. We show that TRIP13 is an oncogenic protein because it accelerates B cell tumor development in transgenic mice. TRIP13-induced resistance to proteasome inhibition can be overcome by a USP7 inhibitor in vitro and in vivo. These findings suggest that TRIP13 expression plays a critical role in B cell lymphoma and MM by regulating deubiquitination of critical oncogenic (NEK2) and tumor suppressor (PTEN, p53) proteins. High TRIP13 identifies a high-risk patient group amenable to adjuvant anti-USP7 therapy.
Sterilizing immunity: New opportunities for rational TB vaccine design
Authors: Alan Sher, Joanne L. Flynn
Journal: The Journal of Experimental Medicine (2021)

Recent studies have revealed situations of high-level naturally acquired and vaccine-induced immunity against Mycobacterium tuberculosis in animal models along with examples of significantly protective immunization in humans. These discoveries offer immunologists new opportunities to define effector mechanisms that when triggered by appropriately engineered vaccines could end TB’s deadly reign.
AB0712 THE INCIDENCE OF SARS-СOV-2 INFECTION IN PATIENTS WITH RHEUMATIC DISEASES ON THERAPY BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS
Authors: A. Dadalova, E. Vasilenko, R. Samigullina, V. Mazurov
Journal: Annals of the Rheumatic Diseases (2021)

Background: At the moment, a highly relevant issue is the course of SARS-CoV-2 infection in patients with rheumatic pathology, especially, those receiving therapy with biological disease modifying antirheumatic drugs. Objectives: of the current study to assess the prevalence and course of SARS-CoV-2 infection in patients receiving various biological disease modifying antirheumatic drugs. Methods: to assess the severity of the course of SARS-CoV-2, discharged epicrisis from hospitals or the conclusion of computed tomography were used. The average age of the patients ranged from 41.4 + 11.6 years. In the evaluated sample, 47 patients (49.47%) were males. Among the infected of SARS-CoV-2 were patients with rheumatoid arthritis - 45 (47.4%), spondyloarthritis - 39 (41.1%), systemic connective tissue diseases - 11 (11.5%). Results: Since March 2020, among the 1319 patients with rheumatic diseases observed at the St. Petersburg Center of therapy biological disease modifying antirheumatic drugs, 95 patients (7,2%) had SARS-CoV-2 infection. In 57,9% (55 patients) there was a mild course of infection, in 35,8% of cases (34 patients) - a moderate course, in 6,3% (6 patients) - a severe course. Inpatient treatment was received by 29,5% (28 patients). A favorable outcome was noted in 95.8%, and a lethal outcome in 4,2%. The use of interleukin-6 inhibitors was required in 2,1% of patients (2) due to the development of a cytokine storm. The structure of the received biological therapy in the severity of the course is shown in Table 1. Table 1. The structure of the received biological therapy in the severity of the course SARS-CoV-2 infection Mild course CT-1 (&lt;25%) CT-2 (25-50%) CT-3 (50-75%) CT-4 (&gt;75%) TNF-α inhibitors, n (%) 30 (31,6) 11 (11,6) 7 (7,3) 3 (3,2) 0 (0,0) anti B-cell therapy (rituximab), n (%) 2 (2,1) 1 (1,1) 2 (2,1) 1 (1,1) 2 (2,1) Abatacept, n (%) 3 (3.2) 0 (0,0) 2 (2,1) 0 (0,0) 0 (0,0) Janus kinase inhibitors, n (%) 5 (5,3) 1 (1,1) 1 (1,1) 0 (0,0) 0 (0,0) Interleukin-6 inhibitors, n (%) 6 (6,3) 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0) Interleukin-17 inhibitors, n (%) 8 (8,4) 2 (2,1) 2 (2,1) 0 (0,0) 0 (0,0) Other, n (%) 1 (1,1) 4 (4,2) 1 (1,1) 0 (0,0) 0 (0,0) Among 95 infected patients, who were observed in the center, 51 received therapy with TNF-α inhibitors (8.5% of the total number of patients receiving therapy), 8 - rituximab therapy (2.7%), 5 - abatacept (6.3%), 7 - Janus kinase inhibitors (0.9%), 6 – interleukin-6 inhibitors (9.2), 12 - interleukin -17 inhibitors (14.1%), 6 patients treated with other drugs (10%). Conclusion: Taking into account the SARS-CoV-2 pandemic, further study of the course of infection in patients with rheumatic diseases, including those receiving biological therapy, is required. More information is also needed on the safety and efficacy of vaccination in this patient population. Disclosure of Interests: None declared
POS0742 SCREENING AND BIOINFORMATICS ANALYSIS OF HUB GENES AND PATHWAYS FOR PRIMARY SJÖGREN’S SYNDROME BASED ON GEO DATABASE
Authors: T. Kong, S. X. Zhang, S. Song, X. Sun, C. Zheng, S. Feng, L. Cheng, G. Shi, X. Li, P. F. He, Q. Yu
Journal: Annals of the Rheumatic Diseases (2021)

Background: Primary Sjögren’s syndrome (pSS) is an autoimmune disease that featured as lymphoplasmacytic infiltration of the exocrine glands leading to sicca symptoms 1 . However, its underlying molecular mechanisms remain elusive. Objectives: This study aims to identify differentially expressed genes (DEGs) and pathways associated with the progression of pSS using bioinformatics analysis and explore its pathogenesis. Methods: The pSS-associated gene chip data set GSE66795 was obtained from the Gene Expression Omnibus (GEO) database, which included 131 cases of fully-phenotyped pSS patients’ whole blood samples and 29 cases of control samples. DEGs were screened Using R software. Online tool Metascape 2 was used to make Gene Ontology (GO) and KEGG pathway enrichment. The PPI network was performed using String database. Hub genes were identified by Cytoscape. Results: A total of 108 DEGs were captured, including 101 up-regulated genes and 7 down-regulated genes. GO enrichment showed that these DEGs were primarily enriched in defense response to virus, response to interferon-gamma, regulation of innate immune response, response to interferon-beta, double-stranded RNA binding, response to interferon-alpha. KEGG pathway enrichment analysis showed these DEGs were principally enriched in Influenza A, RIG-I-like receptor signaling pathway, necroptosis, Staphylococcus aureus infection. Finally, 9 hub genes (STAT1, IRF7, OAS2, GBP1, OAS1, IFIT3, IFIH1, OAS3, DDX60) had highest degree value. Conclusion: The findings identified molecular mechanisms and the key hub genes that may involve in the occurrence and development of pSS. References: [1]Francois H, Mariette X. Renal involvement in primary Sjogren syndrome. Nat Rev Nephrol 2016;12(2):82-93. doi: 10.1038/nrneph.2015.174 [published Online First: 2015/11/17]. [2]Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019;10(1):1523. doi: 10.1038/s41467-019-09234-6 [published Online First: 2019/04/05]. Acknowledgements: This project was supported by National Science Foundation of China (82001740), Open Fund from the Key Laboratory of Cellular Physiology (Shanxi Medical University) (KLCP2019) and Innovation Plan for Postgraduate Education in Shanxi Province (2020BY078). Disclosure of Interests: None declared